伊布替尼
威尼斯人
套细胞淋巴瘤
医学
淋巴瘤
布鲁顿酪氨酸激酶
癌症研究
肿瘤科
内科学
白血病
慢性淋巴细胞白血病
受体
酪氨酸激酶
作者
Constantine S. Tam,Mary Ann Anderson,Christiane Pott,Rishu Agarwal,Sasanka Handunnetti,Rodney J. Hicks,Kate Burbury,G. S. Turner,Juliana Di Iulio,Mathias Bressel,David Westerman,Stephen Lade,Martin Dreyling,Sarah‐Jane Dawson,Mark A. Dawson,John F. Seymour,Andrew W. Roberts
标识
DOI：10.1056/nejmoa1715519
摘要
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cctv18
个性的紫菜
shinysparrow
gjww
maox1aoxin
liv
寻道图强
不跟傻子论短长
lalala
OCDer
壳米
gloval
凤凰
坚强的广山
benben
情怀
阔达可乐
FIN
寻寻觅觅呢
SOLOMON
皖公网安备34019202002308
